Recently, Hangzhou Human Resource and Social Security Bureau released the notice of execution on the major illnesses medical insurance program that 15 drugs with definite therapeutic effects for major illnesses have been added in the scope of major illnesses medical insurance program in Hangzhou, including Remicade^®(Infliximab for Injection).

The four indications of Remicade^®, namely Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease and Psoriasis (commonly known as psora) are all covered in the major illnesses eligible for medical insurance reimbursement program.

The announcement took effect from September 15^th and insurance patients can get support from January 1^st, 2015. 

To get more information, please click the link to read the announcement from government:
https://www.zjhz.lss.gov.cn/html/zcfg/zcfgk/ylbx2/71656.html#